Document:

GenoMed, Inc Exhibit10.18

Exhibit 10.18

                              Contract to Serve on
                      GenoMed's Scientific Advisory Board

Date: 8/15/02

By my signature below I agree to serve as a member of the Scientific Advisory
Board (SAB) of GenoMed, LLC; (the "Company").

I understand and agree that my commitment to the Company is limited to the
following items:

     a. From time to time, to provide advice, consultation or assistance via
telephone conversation, email or FAX.

     b. To provide GenoMed with my curriculum vitae, of which a brief summary,
subject to my final editorial consent, will be included on GenoMed's website (at
www.genomedics.com).

     I understand and agree that I will not at any time or in any manner,
either directly or indirectly, divulge, disclose, or communicate in any manner
any information that is proprietary to the Company. I will protect such
information and treat it as strictly confidential.

     I understand that, as a member of the Company's Scientific Advisory Board,
I may be invited by the Company to participate in additional projects, such as
helping to explain the company's scientific approach to various funding entities
such as venture capital firms, or to analyze the company's scientific data, but
that these additional projects will be negotiated on a case by case basis, and
that I am in no way obligated to perform such duties by the current contract.

     I understand and agree that the Scientific Advisory Board Contract will be
a five (5) year agreement, but that it can be terminated on 30 days' written
notice by either party for any reason whatsoever. The compensation for my
services will be paid by the Company as follows:

1. The option to purchase 100,000 common shares of the Company, exercisable upon
the first anniversary from the date of this Contract.

2. The option to purchase 100,000 common shares of the Company payable upon the
second anniversary from the date of this Contract.

3. The option to purchase 100,000 common shares of the Company payable upon the
third anniversary from the date of this Contract.

4. The option to purchase 100,000 common shares of the Company payable upon the
fourth anniversary from the date of this Contract.

5. The option to purchase 100,000 common shares of the Company payable upon the
fifth anniversary from the date of this Contract.

Signed:/s/ Frank Johnson                     Date 8/15/02

For GenoMed, Inc:
Signed:/s/ David W. Moskowitz                Date 9/3/02GenoMed, Inc. Exhibit 10.19

Exhibit 10.19

                              Contract to Serve on
                       GenoMed's Scientific Advisory Board

Date: 12/11/02

By my signature below I agree to serve as a member of the Scientific Advisory
Board (SAB) of GenoMed, LLC; (the "Company").

I understand and agree that my commitment to the Company is limited to the
following items:

     a. From time to time, to provide advice, consultation or assistance via
telephone conversation, email or FAX.

     b. To provide GenoMed with my curriculum vitae, of which a brief summary,
subject to my final editorial consent, will be included on GenoMed's website (at
www.genomedics.com).

     I understand and agree that I will not at any time or in any manner,
either directly or indirectly, divulge, disclose, or communicate in any manner
any information that is proprietary to the Company. I will protect such
information and treat it as strictly confidential.

     I understand that, as a member of the Company's Scientific Advisory Board,
I may be invited by the Company to participate in additional projects, such as
helping to explain the company's scientific approach to various funding entities
such as venture capital firms, or to analyze the company's scientific data, but
that these additional projects will be negotiated on a case by case basis, and
that I am in no way obligated to perform such duties by the current contract.

     I understand and agree that the Scientific Advisory Board Contract will be
a five (5) year agreement, but that it can be terminated on 30 days' written
notice by either party for any reason whatsoever. The compensation for my
services will be paid by the Company as follows:

1. The option to purchase 100,000 common shares of the Company, exercisable upon
the first anniversary from the date of this Contract.

2. The option to purchase 100,000 common shares of the Company payable upon the
second anniversary from the date of this Contract.

3. The option to purchase 100,000 common shares of the Company payable upon the
third anniversary from the date of this Contract.

4. The option to purchase 100,000 common shares of the Company payable upon the
fourth anniversary from the date of this Contract.

5. The option to purchase 100,000 common shares of the Company payable upon the
fifth anniversary from the date of this Contract.

Signed:/s/ Sergio Danilov                    Date 12/11/02

For GenoMed, Inc:
Signed:/s/ David W. Moskowitz                Date Dec. 11, 2002GenoMed, Inc. Exhibit 10.20

Exhibit 10.20
Scientific Advisory Board Agreement with Geoffrey Boner

                              Contract to Serve on
                       GenoMed's Scientific Advisory Board

Date: December 26, 2002

By my signature below I agree to serve as a member of the Scientific Advisory
Board (SAB) of GenoMed, LLC; (the "Company").

I understand and agree that my commitment to the Company is limited to the
following items:

     a. From time to time, to provide advice, consultation or assistance via
telephone conversation, email or FAX.

     b. To provide GenoMed with my curriculum vitae, of which a brief summary,
subject to my final editorial consent, will be included on GenoMed's website (at
www.genomedics.com).

     I understand and agree that I will not at any time or in any manner,
either directly or indirectly, divulge, disclose, or communicate in any manner
any information that is proprietary to the Company. I will protect such
information and treat it as strictly confidential.

     I understand that, as a member of the Company's Scientific Advisory Board,
I may be invited by the Company to participate in additional projects, such as
helping to explain the company's scientific approach to various funding entities
such as venture capital firms, or to analyze the company's scientific data, but
that these additional projects will be negotiated on a case by case basis, and
that I am in no way obligated to perform such duties by the current contract.

     I understand and agree that the Scientific Advisory Board Contract will be
a five (5) year agreement, but that it can be terminated on 30 days' written
notice by either party for any reason whatsoever. The compensation for my
services will be paid by the Company as follows:

1. The option to purchase 100,000 common shares of the Company, exercisable upon
the first anniversary from the date of this Contract.

2. The option to purchase 100,000 common shares of the Company payable upon the
second anniversary from the date of this Contract.

3. The option to purchase 100,000 common shares of the Company payable upon the
third anniversary from the date of this Contract.

4. The option to purchase 100,000 common shares of the Company payable upon the
fourth anniversary from the date of this Contract.

5. The option to purchase 100,000 common shares of the Company payable upon the
fifth anniversary from the date of this Contract.

Signed:/s/ Geoffrey Boner                    Date 12/26/02

For GenoMed, Inc:
Signed:/s/ David W. Moskowitz                Date 12/26/02GenoMed, Inc. Exhibit 10.21

Exhibit 10.21

                             STOCK OPTION AGREEMENT

THIS AGREEMENT is made effective as of February 22, 2003, between GenoMed, Inc.
a Florida corporation ("Company") and the undersigned ("Director").

WHEREAS, the undersigned has been appointed to serve a one year term as a
Director of the Company, which has an active trading market for its common stock
("Common Stock");

WHEREAS, the Company desires to compensate Directors for past and future
services to the Company by affording the Director an opportunity to purchase
shares of its Common Stock par value $0.0001 (the "Shares"), pursuant to this
Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein
contained, the parties agree as follows:

1.   Grant of Option.The Company hereby grants to the Director, the right and
     option (the "Option") to purchase an aggregate of 1,000,000 Shares on the
     terms and  conditions  of this Option at a price equal to six tenths of a
     cent ($0.006), which represents twenty percent (20%)of the three cent
     ($.03) public bid price of Shares on the date of this Option. The exercise
     price represents the estimated fair market value of the Shares on the date
     of grant of this Option, after giving consideration to the restrictions on
     transfer and other terms and conditions of this Option.

2.   Terms of Exercise.This Option shall be exercisable as to 80,000 Shares on
     March 1, 2002 and as to an additional 80,000 Shares on the first day of
     each month thereafter until the end of February, 2003 after which date it
     shall be exercisable as to all of 1,000,000 Shares (less any for which it
     has been exercised).As an example, on and after March 1, 2002 the Director
     may exercise this Option as to 80,000  Shares;  on and after April 1, 2002
     the Director may exercise this Option as to 160,000 Shares (less any Shares
     as to which the  Director has already exercised this Option);and so on
     until the Director has either exercised this Option as to all of the
     1,000,000 Shares or this Option has earlier lapsed, whichever first occurs.
     Subject to the other terms of this  Agreement, as to any number of Shares
     for which this Option may then be exercised, this Option shall be
     exercisable at any time and from time to time in whole or in part until the
     end of the day on a date three (3) years from the date hereof, and upon the
     third anniversary of this agreement, this Option shall terminate as to any
     Shares which have not by then been purchased.

3.   Procedure.Exercise of this Option shall be by delivery or written notice
     to the Company in such form as the Company reasonably shall require at its
     principal office in St. Louis, Missouri, specifying the number of Shares
     with respect to which this Option is being exercised.Cash or a certified
     check in the amount equal to the full price of the Shares to be  purchased
     shall accompany such written notice.

4.   Rights as Shareholder.The Director shall only have or exercise the rights
     of a shareholder with respect to the Shares subject to this Option after
     the Shares have been issued to him upon exercise of the Option, and not
     before its exercise.

5.   Stock Splits.In the event that prior to the purchase of the maximum number
     purchasable under this Option the Company shall have effected one or more
     reclassifications,combinations,stock dividends or split-ups of the Common
     Shares of  the Company, or other like transactions, or mergers,
     consolidations  or other  transactions  relating to the Common Shares,  the
     number of Shares thereafter purchasable under this option shall be
     adjusted, upward or downward, by the Board of Directors of the Company as
     equitable to prevent dilution or enlargement of the option right herein
     granted.In the event of an acquisition or merger in which the Company
     loses its identity, all outstanding Options shall be honored by the
     successor.

6.   Legal Requirements.The Director shall comply with all applicable laws and
     regulations regarding the purchase and sale of securities by a Director in
     a company with shares trading in a public market and shall file all
     required reports on a timely basis.

7.   Specific Performance.The parties hereto hereby agree that they will be
     irreparably damaged in the event of any controversy concerning the right or
     obligation shall be enforceable in a court of equity by a decree or
     specific performance.Such remedy shall,however, be cumulative and
     nonexclusive, and shall be in addition to any other remedy which the
     parties may have.

8.   General.The Director understands and acknowledges that upon exercise of
     this Option,Shares purchased may not be sold, transferred, pledged or
     otherwise disposed of unless the Shares are registered under the Securities
     Act of 1933, or unless the Company has received an opinion from counsel
     satisfactory to the Company that said regulation is not required.When the
     Company becomes eligible to use federal Form s-8 for the registration of
     its Common Stock, the Company will upon request of any of the undersigned,
     register the shares purchased upon the exercise of this Option.

9.   Benefit.The Option is being issued in reliance upon an exemption from
     registration under the Securities Act of 1933 and comparable provisions of
     State statues, and may only be transferred when so registered, or in
     accordance with exemptions from such registration. This Option cannot be
     sold, transferred or otherwise disposed of by the holder  hereof to any
     other person or entity unless such transaction is registered under the
     Securities Act of 1933, as amended, and under applicable laws of the state
     or jurisdiction where such transaction  occurs, or unless such transaction
     shall qualify under an allowed exemption to such registration. As a
     condition to transferring this Option on the books of the Corporation, the
     holder hereof may be required to furnish the Corporation with an option of
     legal counsel satisfactory to the Corporation to the effect that the
     transaction complies with applicable securities laws.

10.  Miscellaneous. This agreement may be amended by the parties only by a
     writing signed by the party against whom enforcement is sought.This
     agreement shall insure to the benefit of and be binding upon the parties
     and their heirs and permitted successors and assigns.

IN WITNESS WHEREOF, the Company has duly executed this Agreement and the
Director has hereunto set his hand as of the day and year first below written.

GenoMed, Inc.

By: /s/David W. Moskowitz                                    Date: 2-22-02
David W. Moskowitz
Chairman and Chief Medical Officer

By: /s/Peter C. Brooks
Peter C. Brooks
Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]